HC Wainwright Forecasts Strong Price Appreciation for Bicara Therapeutics (NASDAQ:BCAX) Stock

Bicara Therapeutics (NASDAQ:BCAXGet Free Report) had its target price hoisted by equities researchers at HC Wainwright from $42.00 to $45.00 in a research note issued on Monday,Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s target price indicates a potential upside of 275.63% from the stock’s previous close.

A number of other analysts also recently commented on BCAX. Stifel Nicolaus started coverage on Bicara Therapeutics in a research report on Tuesday, October 8th. They set a “buy” rating and a $47.00 target price on the stock. RODMAN&RENSHAW upgraded shares of Bicara Therapeutics to a “strong-buy” rating in a research report on Tuesday, November 5th. Rodman & Renshaw began coverage on shares of Bicara Therapeutics in a report on Tuesday, November 5th. They set a “buy” rating and a $48.00 target price for the company. Morgan Stanley began coverage on shares of Bicara Therapeutics in a research report on Tuesday, October 8th. They set an “overweight” rating and a $35.00 target price for the company. Finally, Cantor Fitzgerald began coverage on shares of Bicara Therapeutics in a research note on Tuesday, October 8th. They set an “overweight” rating for the company. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $43.75.

View Our Latest Stock Analysis on BCAX

Bicara Therapeutics Stock Performance

NASDAQ:BCAX opened at $11.98 on Monday. The stock’s fifty day moving average is $16.79. Bicara Therapeutics has a fifty-two week low of $11.10 and a fifty-two week high of $28.09.

Bicara Therapeutics (NASDAQ:BCAXGet Free Report) last issued its earnings results on Tuesday, November 12th. The company reported ($1.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.46) by ($1.14). As a group, equities research analysts expect that Bicara Therapeutics will post -2.59 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Bicara Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. RA Capital Management L.P. purchased a new position in shares of Bicara Therapeutics during the 3rd quarter worth $177,169,000. FMR LLC purchased a new position in Bicara Therapeutics during the third quarter worth about $57,913,000. Braidwell LP acquired a new stake in Bicara Therapeutics in the 3rd quarter worth about $42,219,000. Janus Henderson Group PLC acquired a new position in shares of Bicara Therapeutics during the 3rd quarter valued at about $30,329,000. Finally, Baker BROS. Advisors LP purchased a new position in shares of Bicara Therapeutics during the 3rd quarter worth about $21,225,000.

Bicara Therapeutics Company Profile

(Get Free Report)

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.

See Also

Analyst Recommendations for Bicara Therapeutics (NASDAQ:BCAX)

Receive News & Ratings for Bicara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bicara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.